Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw unusually-strong trading volume on Thursday. 4,501 shares changed hands during mid-day trading, a decline of 34% from the previous session’s volume of 6,784 shares. The stock last traded at $14.62 and had previously closed at $14.85.

Analyst Ratings Changes

Several brokerages recently commented on AAPG. BTIG Research reaffirmed a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Citizens Jmp assumed coverage on shares of Ascentage Pharma Group International in a research note on Tuesday. They issued a “market outperform” rating and a $35.00 target price on the stock. Citigroup started coverage on shares of Ascentage Pharma Group International in a report on Tuesday. They issued a “buy” rating and a $46.00 price target for the company. Finally, JPMorgan Chase & Co. cut their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a report on Thursday, October 8th. Two analysts have rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $43.90.

Ascentage Pharma Group International Stock Up 0.1%

The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09. The business’s fifty day moving average price is $16.60 and its 200-day moving average price is $19.17.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The company had revenue of $22.24 million during the quarter. On average, equities analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.